阿昔洛韦治疗机械通气患者口咽部单纯疱疹病毒再激活:一项随机临床试验
该双盲、安慰剂对照随机临床试验在法国16个ICU纳入239例机械通气≥96小时且口咽部HSV再激活的成人,随机接受静脉阿昔洛韦5 mg/kg每日3次共14天或安慰剂。主要终点60天无呼吸机天数中位数阿昔洛韦组35天、安慰剂组36天(P=.17),无显著差异。60天死亡率阿昔洛韦组22% vs 安慰剂组33%(风险差0.11,95%CI -0.004至0.22,P=.06)。不良事件频率两组相似(28% vs 23%,P=.40)。结论认为该结果不支持在此类患者中常规抢先使用阿昔洛韦。
要点
- 纳入标准:成人机械通气≥96小时且继续通气≥48小时,口咽部HSV再激活,随机接受静脉阿昔洛韦5 mg/kg每日3次共14天或安慰剂。
- 主要终点60天无呼吸机天数中位数阿昔洛韦组35天(IQR 0-53)vs 安慰剂组36天(IQR 0-50),P=.17,无显著差异。
- 60天死亡率阿昔洛韦组22%(26例)vs 安慰剂组33%(39例),风险差0.11(95%CI -0.004至0.22),P=.06,未达统计学显著。
- 不良事件频率两组相似(阿昔洛韦组28% vs 安慰剂组23%,P=.40),随机后急性肾衰竭阿昔洛韦组3例(3%)vs 安慰剂组2例(2%)。
- 结论:阿昔洛韦未增加60天无呼吸机天数,不提示支持该人群常规抢先使用阿昔洛韦。
适用人群与场景
- 法国16个ICU的成人(年龄>18岁),机械通气至少96小时且继续机械通气48小时或以上,伴口咽部HSV再激活。
- 纳入时间2014年2月2日至2018年2月22日。
处置流程与药物剂量
- 静脉阿昔洛韦5 mg/kg,每日3次,疗程14天,或匹配安慰剂。
研究设计与关键结果
- 双盲、安慰剂对照随机临床试验,16个ICU,239例随机,1例撤回知情同意,238例(阿昔洛韦组119例、安慰剂组119例)纳入主要终点分析;中位年龄61岁(IQR 50-70),女性76例(32%)。
- 主要终点60天无呼吸机天数中位数阿昔洛韦组35天(IQR 0-53)vs 安慰剂组36天(IQR 0-50),P=.17。
- 60天死亡率阿昔洛韦组22%(26例)vs 安慰剂组33%(39例),风险差0.11(95%CI -0.004至0.22),P=.06。
- 不良事件频率阿昔洛韦组28% vs 安慰剂组23%,P=.40;随机后急性肾衰竭阿昔洛韦组3例(3%)vs 安慰剂组2例(2%);因治疗相关不良事件停药阿昔洛韦组4例(3%)vs 安慰剂组0例。
证据类型、等级与局限
- 证据类型:双盲、安慰剂对照随机临床试验(RCT)。
- 原文结论:该结果不支持在此类患者中常规抢先使用阿昔洛韦。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对机械通气≥96小时且口咽部HSV再激活的成人,阿昔洛韦5 mg/kg每日3次共14天未增加60天无呼吸机天数,作者认为该结果不支持常规抢先使用阿昔洛韦。
- 60天死亡率阿昔洛韦组22% vs 安慰剂组33%,风险差0.11(95%CI -0.004至0.22)未达统计学显著,原文未据此给出推荐。
指南或共识出处
- 临床试验注册号:ClinicalTrials.gov NCT02152358。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The role of herpes simplex virus (HSV) reactivation on morbidity and mortality in patients in the intensive care unit requiring mechanical ventilation remains unknown.
OBJECTIVE: To determine whether preemptive treatment with intravenous acyclovir reduces the duration of mechanical ventilation in patients with HSV oropharyngeal reactivation.
DESIGN, SETTING, AND PARTICIPANTS: A double-blind, placebo-controlled randomized clinical trial was conducted in 16 intensive care units in France. Participants included 239 adults (age, >18 years) who received mechanical ventilation for at least 96 hours and continued to receive mechanical ventilation for 48 hours or more, with HSV oropharyngeal reactivation. Patients were enrolled between February 2, 2014, and February 22, 2018.
INTERVENTIONS: Participants were randomized to receive intravenous acyclovir, 5 mg/kg, 3 times daily for 14 days or a matching placebo.
MAIN OUTCOMES AND MEASURES: The primary end point was ventilator-free days from randomization to day 60. Prespecified secondary outcomes included mortality at 60 days. Main analyses were conducted on an intention-to-treat basis.
RESULTS: Of 239 patients enrolled and randomized, 1 patient withdrew consent, leaving 238 patients, with 119 patients in both the acyclovir and placebo (control) groups (median [IQR] age, 61 [50-70] years; 76 [32%] women) available for primary outcome measurement. On day 60, the median (IQR) numbers of ventilator-free days were 35 (0-53) for acyclovir recipients and 36 (0-50]) for controls (P = .17 for between-group comparison). Among secondary outcomes, 26 patients (22%) and 39 patients (33%) had died at day 60 (risk difference, 0.11, 95% CI, -0.004 to 0.22, P = .06). The adverse event frequency was similar for both groups (28% in the acyclovir group and 23% in the placebo group, P = .40), particularly acute renal failure post randomization affecting 3 acyclovir recipients (3%) and 2 controls (2%). Four patients (3%) in the acyclovir group vs none in the placebo group stopped the study drug for treatment-related adverse events.
CONCLUSIONS AND RELEVANCE: In patients receiving mechanical ventilation for 96 hours or more with HSV reactivation in the throat, use of acyclovir, 5 mg/kg, 3 times daily for 14 days, did not increase the number of ventilator-free days at day 60, compared with placebo. These findings do not appear to support routine preemptive use of acyclovir in this setting.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02152358.
参考来源
- Luyt CE, Forel JM, Hajage D, et al. Acyclovir for Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation: A Randomized Clinical Trial. JAMA Intern Med. 2020. PMID: 31841577. doi:10.1001/jamainternmed.2019.5713
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。